These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 33275063)

  • 21. Electrophilic warheads in covalent drug discovery: an overview.
    Péczka N; Orgován Z; Ábrányi-Balogh P; Keserű GM
    Expert Opin Drug Discov; 2022 Apr; 17(4):413-422. PubMed ID: 35129005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarkers to improve the benefit/risk balance for approved therapeutics: a US FDA perspective on personalized medicine.
    Sapsford KE; Tezak Z; Kondratovich M; Pacanowski MA; Zineh I; Mansfield E
    Ther Deliv; 2010 Nov; 1(5):631-41. PubMed ID: 22833953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Precision" drug development?
    Woodcock J
    Clin Pharmacol Ther; 2016 Feb; 99(2):152-4. PubMed ID: 26331240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity.
    Ferguson FM; Doctor ZM; Ficarro SB; Browne CM; Marto JA; Johnson JL; Yaron TM; Cantley LC; Kim ND; Sim T; Berberich MJ; Kalocsay M; Sorger PK; Gray NS
    Cell Chem Biol; 2019 Jun; 26(6):804-817.e12. PubMed ID: 30930164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors.
    Reid TE; Fortunak JM; Wutoh A; Simon Wang X
    Curr Top Med Chem; 2016; 16(13):1452-62. PubMed ID: 26369823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemoproteomic methods for covalent drug discovery.
    Chan WC; Sharifzadeh S; Buhrlage SJ; Marto JA
    Chem Soc Rev; 2021 Aug; 50(15):8361-8381. PubMed ID: 34143170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted covalent drugs of the kinase family.
    Singh J; Petter RC; Kluge AF
    Curr Opin Chem Biol; 2010 Aug; 14(4):475-80. PubMed ID: 20609616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The advantages of describing covalent inhibitor in vitro potencies by IC
    Thorarensen A; Balbo P; Banker ME; Czerwinski RM; Kuhn M; Maurer TS; Telliez JB; Vincent F; Wittwer AJ
    Bioorg Med Chem; 2021 Jan; 29():115865. PubMed ID: 33285410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In silico identification of novel kinase inhibitors targeting wild-type and T315I mutant ABL1 from FDA-approved drugs.
    Xu HL; Wang ZJ; Liang XM; Li X; Shi Z; Zhou N; Bao JK
    Mol Biosyst; 2014 Jun; 10(6):1524-37. PubMed ID: 24691568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
    Albin N; Mc Leer A; Sakhri L
    Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.
    Bauer RA
    Drug Discov Today; 2015 Sep; 20(9):1061-73. PubMed ID: 26002380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Approaches to mitigate the risk of serious adverse reactions in covalent drug design.
    Baillie TA
    Expert Opin Drug Discov; 2021 Mar; 16(3):275-287. PubMed ID: 33006907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2018 Feb; 23(3):. PubMed ID: 29495494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery and Development of a Series of Pyrazolo[3,4-
    Wang Y; Dai Y; Wu X; Li F; Liu B; Li C; Liu Q; Zhou Y; Wang B; Zhu M; Cui R; Tan X; Xiong Z; Liu J; Tan M; Xu Y; Geng M; Jiang H; Liu H; Ai J; Zheng M
    J Med Chem; 2019 Aug; 62(16):7473-7488. PubMed ID: 31335138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32050446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation.
    Puthumana J; Wallach JD; Ross JS
    JAMA; 2018 Jul; 320(3):301-303. PubMed ID: 30027239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other Medicines.
    Pregelj L; Hwang TJ; Hine DC; Siegel EB; Barnard RT; Darrow JJ; Kesselheim AS
    Health Aff (Millwood); 2018 May; 37(5):724-731. PubMed ID: 29733717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Communication in Drug Development: "Translating" Scientific Discovery.
    Settleman J; Cohen RL
    Cell; 2016 Mar; 164(6):1101-1104. PubMed ID: 26967277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.
    Kazandjian D; Blumenthal GM; Yuan W; He K; Keegan P; Pazdur R
    Clin Cancer Res; 2016 Mar; 22(6):1307-12. PubMed ID: 26980062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.